Full Press Release Details
IceCure's ProSense System Used in Endometriosis
Cryoablation Study That
Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery
CAESAREA, Israel, April 20, 2023 -- IceCure
Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of minimally-invasive cryoablation technology, the ProSense System, that destroys
tumors by freezing as an alternative to surgical tumor removal, today announced that its ProSense system was used in a single-site study
conducted at the Sorbonne University Department of Interventional Radiology and Oncology, Tenon Hospital in Paris, France by lead investigator
Francois H. Cornelis, MD, PhD and a team of doctors. The study titled "Pain-Free Survival After Percutaneous Image-Guided Cryoablation
of Extraperitoneal Endometriosis" was published in the Journal of Vascular and Interventional Radiology. The independent
study and published paper were not sponsored by IceCure. Dr. Cornelis presented the study data at the Society of Interventional Radiology
2023 Annual Scientific Meeting on March 8, 2023.
Cryoprobes used in the study were of two types: IceCure's ProSense
cryoprobe and Varian's V-probe. The purpose of the study was to retrospectively evaluate the pain-free survival of percutaneous
(minimally invasive, through the skin) image-guided cryoablation of symptomatic extraperitoneal endometriosis ("EE"). 42 patients
with a total of 47 lesions were treated. Patients were made aware that cryoablation was offered as a minimally invasive alternative to
surgery, and that a surgical procedure may be performed if cryoablation failed. According to the published study, the therapeutic options
thus far to avoid the progression of endometriosis and reduce symptoms have been limited to hormonal agents and wide surgical excision.
During the last decades, minimally invasive techniques such as cryoablation have been suggested as a promising option to treat abdominal
wall endometriosis with satisfactory outcomes and low morbidity.
Based on the following study outcome data, the
study concluded that percutaneous cryoablation is a safe and effective procedure that significantly reduces pain and obtains local control
of EE. The median follow-up was 13.5 months after cryoablation. The study's conclusions included:
"We are grateful to Dr. Cornelis and the
team of doctors at Sorbonne University and Tenon Hospital, where the data was collected, for having used our ProSense system, in addition
to those from another company, as part of this independent study. Tenon Hospital institution is highly regarded in the field of gynecology
and interventional radiology. We believe that the independent study has demonstrated the value of cryoablation in treating endometriosis,
a chronic and painful condition in dire need of an effective minimally invasive treatment," stated Eyal Shamir, IceCure's
Chief Executive Officer. "The ProSense system has regulatory approval in several countries, including FDA clearance for use as a
cryosurgical tool in gynecology, and we are pleased that doctors now have more evidence of cryoablation's efficacy in patients with
extraperitoneal endometriosis."
According to the World Health Organization, endometriosis
affects about 10% of women who are at reproductive age globally, or 190 million people. Endometriosis is a chronic disease associated
with severe, life-impacting symptoms. Many individuals suffering from it have limited awareness of the condition causing a lengthy delay
between onset of symptoms and diagnosis. Current treatments are aimed at controlling symptoms. EE may be observed incidentally but more
often on surgical scars in women with or without a history of endometriosis.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM)
(TASE: ICCM) develops and markets ProSense , an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign
and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology
is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system
is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
Email: mpolyviou@evcgroup.com
Email: tkehrli@evcgroup.com